{"id":"https://openalex.org/W1968448903","doi":"https://doi.org/10.3109/15569527.2011.647179","title":"Exanthematous drug eruption due to valsartan","display_name":"Exanthematous drug eruption due to valsartan","publication_year":2012,"publication_date":"2012-01-18","ids":{"openalex":"https://openalex.org/W1968448903","doi":"https://doi.org/10.3109/15569527.2011.647179","mag":"1968448903","pmid":"https://pubmed.ncbi.nlm.nih.gov/22257082"},"language":"en","primary_location":{"id":"doi:10.3109/15569527.2011.647179","doi":"https://doi.org/10.3109/15569527.2011.647179","is_oa":false,"landing_page_url":"https://doi.org/10.3109/15569527.2011.647179","pdf_url":null,"source":{"id":"https://openalex.org/S52317855","display_name":"Cutaneous and Ocular Toxicology","issn_l":"1556-9527","issn":["1556-9527","1556-9535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cutaneous and Ocular Toxicology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102781068","display_name":"G\u00fcnseli \u00d6zt\u00fcrk","orcid":"https://orcid.org/0000-0002-9936-4116","observed_orcids":["https://orcid.org/0000-0002-9936-4116"]},"institutions":[{"id":"https://openalex.org/I41641357","display_name":"Ege University","ror":"https://ror.org/02eaafc18","country_code":"TR","type":"education","lineage":["https://openalex.org/I41641357"]}],"countries":["TR"],"is_corresponding":false,"raw_author_name":"Gunseli Ozturk","raw_affiliation_strings":["Department of Dermatology and Venerology, Ege University Medical Faculty, Izmir, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology and Venerology, Ege University Medical Faculty, Izmir, Turkey","institution_ids":["https://openalex.org/I41641357"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050837035","display_name":"Beng\u00fc Ger\u00e7eker T\u00fcrk","orcid":"https://orcid.org/0000-0002-3926-4199","observed_orcids":["https://orcid.org/0000-0002-3926-4199"]},"institutions":[{"id":"https://openalex.org/I41641357","display_name":"Ege University","ror":"https://ror.org/02eaafc18","country_code":"TR","type":"education","lineage":["https://openalex.org/I41641357"]}],"countries":["TR"],"is_corresponding":false,"raw_author_name":"Bengu Gerceker Turk","raw_affiliation_strings":["Ege University Medical Faculty, Department of Dermatology and Venerology, Izmir, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ege University Medical Faculty, Department of Dermatology and Venerology, Izmir, Turkey","institution_ids":["https://openalex.org/I41641357"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079632150","display_name":"Bircan Senturk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I41641357","display_name":"Ege University","ror":"https://ror.org/02eaafc18","country_code":"TR","type":"education","lineage":["https://openalex.org/I41641357"]}],"countries":["TR"],"is_corresponding":false,"raw_author_name":"Bircan Senturk","raw_affiliation_strings":["Ege University Medical Faculty, Department of Dermatology and Venerology, Izmir, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ege University Medical Faculty, Department of Dermatology and Venerology, Izmir, Turkey","institution_ids":["https://openalex.org/I41641357"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101914394","display_name":"Meltem T\u00fcrkmen","orcid":"https://orcid.org/0000-0003-1216-2253","observed_orcids":["https://orcid.org/0000-0003-1216-2253"]},"institutions":[{"id":"https://openalex.org/I41641357","display_name":"Ege University","ror":"https://ror.org/02eaafc18","country_code":"TR","type":"education","lineage":["https://openalex.org/I41641357"]}],"countries":["TR"],"is_corresponding":true,"raw_author_name":"Meltem Turkmen","raw_affiliation_strings":["Ege University Medical Faculty, Department of Dermatology and Venerology, Izmir, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ege University Medical Faculty, Department of Dermatology and Venerology, Izmir, Turkey","institution_ids":["https://openalex.org/I41641357"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066513882","display_name":"G\u00fcl\u015fen Kandilo\u011flu","orcid":"https://orcid.org/0000-0003-1861-1240","observed_orcids":["https://orcid.org/0000-0003-1861-1240"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gulsen Kandiloglu","raw_affiliation_strings":["Department of Pathology, Izmir, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Izmir, Turkey","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5101914394"],"corresponding_institution_ids":["https://openalex.org/I41641357"],"apc_list":null,"apc_paid":null,"fwci":0.862,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.71336541,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"31","issue":"4","first_page":"335","last_page":"337"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12796","display_name":"Dermatological and COVID-19 studies","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11033","display_name":"Contact Dermatitis and Allergies","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valsartan","display_name":"valsartan","score":0.9990000128746033},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9049999713897705},{"id":"https://openalex.org/keywords/drug-induced-skin-reaction","display_name":"drug-induced skin reaction","score":0.9369999766349792},{"id":"https://openalex.org/keywords/maculopapular-eruption","display_name":"maculopapular eruption","score":0.9129999876022339},{"id":"https://openalex.org/keywords/antihypertensive-drugs","display_name":"antihypertensive drugs","score":0.6919999718666077},{"id":"https://openalex.org/keywords/drug-hypersensitivity","display_name":"drug hypersensitivity","score":0.6359999775886536},{"id":"https://openalex.org/keywords/eosinophilic-dermatoses","display_name":"eosinophilic dermatosis","score":0.7120000123977661},{"id":"https://openalex.org/keywords/skin-histopathology","display_name":"skin histopathology","score":0.6230000257492065}],"concepts":[{"id":"https://openalex.org/C2777387769","wikidata":"https://www.wikidata.org/wiki/Q155472","display_name":"Valsartan","level":3,"score":0.967440664768219},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7967305183410645},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5743180513381958},{"id":"https://openalex.org/C2779121184","wikidata":"https://www.wikidata.org/wiki/Q1166142","display_name":"Erythema","level":2,"score":0.4916422963142395},{"id":"https://openalex.org/C2779515644","wikidata":"https://www.wikidata.org/wiki/Q718675","display_name":"Drug eruption","level":3,"score":0.48873186111450195},{"id":"https://openalex.org/C2777624698","wikidata":"https://www.wikidata.org/wiki/Q505531","display_name":"Dermis","level":2,"score":0.4303600788116455},{"id":"https://openalex.org/C104849204","wikidata":"https://www.wikidata.org/wiki/Q24778533","display_name":"Angiotensin receptor","level":4,"score":0.4154735803604126},{"id":"https://openalex.org/C2780192228","wikidata":"https://www.wikidata.org/wiki/Q575890","display_name":"Antihypertensive drug","level":3,"score":0.41506001353263855},{"id":"https://openalex.org/C2779646130","wikidata":"https://www.wikidata.org/wiki/Q411347","display_name":"Amlodipine","level":3,"score":0.41436532139778137},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3924848735332489},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.38555967807769775},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.32037949562072754},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2799376845359802},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.2662346363067627},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.09489893913269043},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.08403158187866211}],"mesh":[{"descriptor_ui":"D000068756","descriptor_name":"Valsartan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D003875","descriptor_name":"Drug Eruptions","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D003875","descriptor_name":"Drug Eruptions","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D004890","descriptor_name":"Erythema","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D004890","descriptor_name":"Erythema","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.3109/15569527.2011.647179","doi":"https://doi.org/10.3109/15569527.2011.647179","is_oa":false,"landing_page_url":"https://doi.org/10.3109/15569527.2011.647179","pdf_url":null,"source":{"id":"https://openalex.org/S52317855","display_name":"Cutaneous and Ocular Toxicology","issn_l":"1556-9527","issn":["1556-9527","1556-9535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cutaneous and Ocular Toxicology","raw_type":"journal-article"},{"id":"pmid:22257082","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22257082","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cutaneous and ocular toxicology","raw_type":"Case Reports"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W19966678","https://openalex.org/W571455068","https://openalex.org/W1967299500","https://openalex.org/W1997735787","https://openalex.org/W2076901831","https://openalex.org/W2106061969","https://openalex.org/W2128975519","https://openalex.org/W2165133881","https://openalex.org/W2278802718","https://openalex.org/W2312658792","https://openalex.org/W2335316930","https://openalex.org/W2461739133","https://openalex.org/W2469696943","https://openalex.org/W4243805048"],"related_works":["https://openalex.org/W3091489194","https://openalex.org/W7143500973","https://openalex.org/W2128975519","https://openalex.org/W2076901831","https://openalex.org/W2032293818","https://openalex.org/W2906620590","https://openalex.org/W2278802718","https://openalex.org/W2394455268","https://openalex.org/W2312658792","https://openalex.org/W2097335509"],"abstract_inverted_index":{"OBJECTIVE:":[0],"Valsartan":[1],"is":[2],"an":[3,194],"angiotensin":[4],"II":[5],"receptor":[6],"blocker":[7],"(ARB)":[8],"used":[9,182],"for":[10,65],"treatment":[11],"of":[12,18,37,70,77,97,168,174,179,193],"hypertension.":[13],"The":[14,120],"well-known":[15],"adverse":[16],"effects":[17,28,167,178],"valsartan":[19,63,78,129,185],"are":[20,159],"dizziness,":[21],"headache":[22],"and":[23,86,109,133,184],"cough.":[24],"Valsartan-related":[25],"cutaneous":[26,154,165,176],"side":[27,155,166,177],"have":[29,152],"been":[30,59],"reported":[31],"previously":[32],"in":[33,106,117],"a":[34,93,160,190],"limited":[35],"number":[36],"case":[38],"reports.":[39],"MATERIALS":[40],"AND":[41,137],"METHODS:":[42],"A":[43],"47-year-old":[44],"man":[45],"admitted":[46],"with":[47,130],"diffuse,":[48],"itchy":[49],"erythematous":[50],"maculopapular":[51],"eruption":[52],"all":[53],"over":[54,83],"the":[55,71,74,84,89,98,107,118,164,175],"body.":[56],"He":[57],"has":[58],"taking":[60],"160":[61],"mg":[62],"daily":[64],"10":[66],"days":[67],"before":[68],"onset":[69],"eruption.":[72],"On":[73],"third":[75],"day":[76],"therapy,":[79],"erythema":[80],"had":[81],"appeared":[82],"face":[85],"spread":[87],"throughout":[88],"whole":[90],"body":[91],"within":[92],"week.":[94],"Histopathologic":[95],"examination":[96],"lesions":[99],"showed":[100],"lymphocyte":[101],"exocytosis,":[102],"spongiosis,":[103],"necrotic":[104],"keratinocytes":[105],"epidermis,":[108],"mixed":[110],"inflammatory":[111],"cell":[112],"infiltrates":[113],"including":[114,143],"perivascular":[115],"eosinophils":[116],"dermis.":[119],"patient":[121],"was":[122],"diagnosed":[123],"as":[124,189],"drug":[125,196],"reaction":[126],"due":[127],"to":[128],"historical,":[131],"clinical":[132],"histopathologic":[134],"features.":[135],"DISCUSSION":[136],"CONCLUSION:":[138],"Most":[139],"common":[140],"antihypertensive":[141],"agents":[142],"diuretics,":[144],"beta":[145],"blockers,":[146,148],"calcium-channel":[147],"angiotensin-converting":[149],"enzyme":[150],"inhibitors":[151],"many":[153],"effects.":[156],"However,":[157],"there":[158],"few":[161],"reports":[162],"about":[163],"ARBs.":[169],"Physicians":[170],"should":[171,186],"be":[172,187],"aware":[173],"this":[180],"commonly":[181],"agent":[183],"considered":[188],"triggering":[191],"factor":[192],"exanthematous":[195],"reactions.":[197]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}